Androgen Suppression Primes PSMA-Targeted Agents in Resistant Prostate Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing prostate cancer treatments based on androgen suppression face challenges due to inconsistent androgen receptor (AR) regulation of prostate-specific membrane antigen (PSMA) expression, leading to resistance and limited therapeutic efficacy, particularly in castrate-resistant cases.
Innovation Solution
Exploiting the inverse relationship between androgen levels and PSMA expression by combining anti-androgen therapy with PSMA-targeted cytotoxic agents, leveraging the conditionally enhanced vulnerability of prostate cancer cells to PSMA-targeted therapies, even in castrate-resistant patients.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If androgen suppression therapy is used to treat prostate cancer, then tumor growth is inhibited, but PSMA expression becomes inconsistent and resistance develops
Solution Approach 1:
The patent changes the parameter of PSMA expression levels by using androgen suppression therapy to up-regulate PSMA expression on prostate cancer cells. This parameter change makes the tumor cells more vulnerable to PSMA-targeted therapies, thereby improving therapeutic efficacy and overcoming resistance
Solution Approach 2:
The patent applies androgen suppression therapy as a preliminary action before administering PSMA-targeted therapy. This preliminary up-regulation of PSMA expression ensures that the tumor cells are in a state of enhanced vulnerability when the PSMA-targeted agent is introduced, improving the overall treatment outcome
2Speed
If androgen levels are suppressed to treat prostate cancer, then tumor progression is slowed, but PSMA expression regulation becomes unpredictable
Solution Approach 1:
The patent utilizes the feedback mechanism where androgen suppression therapy induces up-regulation of PSMA expression. This feedback loop creates a predictable pattern where reduced androgen levels lead to increased PSMA expression, making the regulation predictable and exploitable for combination therapy
3Device complexity
If PSMA-targeted therapy is administered alone, then treatment is simple, but therapeutic efficacy is limited due to low PSMA expression
Solution Approach 1:
The patent merges two therapies: androgen suppression therapy and PSMA-targeted therapy. By combining these treatments, the patent achieves synergistic efficacy where androgen suppression up-regulates PSMA expression, making the tumor cells more susceptible to PSMA-targeted agents, thereby improving overall therapeutic outcome
Data Source
AI summary
Anti-androgen therapies represent the cornerstone of prostate cancer (PC) treatment. Yet all PC patients ultimately fail efforts to rein in the androgen receptor (AR). This invention is based on the discovery that prostate-specific membrane antigen (PSMA), a highly PC-specific and clinically validated cell surface target, is AR-suppressed and up-regulated in PC as a result of hormonal manipulation. This up-regulation occurs in an unexpected timeframe and it occurs even in the castrate-resistant setting. As a result, hormonal therapy creates a state of conditionally enhanced vulnerability of PC to PSMA-targeted anti-cancer/cytotoxic agents that can be exploited by leveraging anti-AR therapy by the addition of PSMA-targeted agents. We demonstrate this conditionally enhanced vulnerability in a castrate-resistant animal model. The state of conditionally enhanced vulnerability may be relevant for other cancer targets and efforts to screen for them may improve other cancer therapies.